TISstudent,Thank you for that information.It would appear from...

TISstudent,

Thank you for that information.

It would appear from the Bioshares report that TIS may now go to the 'top of the class'!

If Shire Pharmaceuticals paid $750M for a product that has now fallen short of expectations - well the end point for TIS in my opinion looks excellent.

Not too sure that a 500 person trial will show anything different to what has already been achieved.

The 'commercial partner' is scheduled to be announced before the end of this quarter.

I wait with strong anticipation!!

Regards...............